enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
enGene Holdings Inc. (Nasdaq: ENGN) has granted an inducement equity award to Joan Connolly, the company's new Chief Technology Officer. The award, granted on October 21, 2024, consists of a non-qualified stock option to purchase 210,000 common shares at an exercise price of $9.83 per share, equal to the closing price on the grant date.
The stock option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This grant was made outside of enGene's 2023 Incentive Equity Plan but will have consistent terms and conditions. The award was approved by the independent Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) ha concesso un premio azionario di induzione a Joan Connolly, il nuovo Chief Technology Officer dell'azienda. Il premio, concesso il 21 ottobre 2024, consiste in un
L'opzione azionaria ha un termine di 10 anni e si maturerà nel corso di quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi tre anni. Questa concessione è stata effettuata al di fuori del Piano di Incentivi Azionari 2023 di enGene, ma avrà termini e condizioni coerenti. Il premio è stato approvato dal Comitato per la Compensazione indipendente in conformità con il Regolamento di quotazione NASDAQ 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) ha otorgado un premio de incentivo en acciones a Joan Connolly, la nueva Directora de Tecnología de la empresa. El premio, otorgado el 21 de octubre de 2024, consiste en una opción de acciones no calificadas para comprar 210,000 acciones ordinarias a un precio de ejercicio de $9.83 por acción, igual al precio de cierre en la fecha de concesión.
La opción de acciones tiene un plazo de 10 años y se otorgará en cuatro años, con el 25% otorgado después de un año y el resto otorgado mensualmente durante los siguientes tres años. Este otorgamiento se realizó fuera del Plan de Incentivos en Acciones 2023 de enGene, pero tendrá términos y condiciones consistentes. El premio fue aprobado por el Comité de Compensación independiente de acuerdo con la Regla de Cotización NASDAQ 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN)는 새로 임명된 최고 기술 책임자(Joan Connolly)에게 유인 주식을 수여했습니다. 이 상은 2024년 10월 21일에 수여되었으며, 210,000주를 구매할 수 있는 비인증 주식 매수 옵션으로 구성되어 있으며, 행사 가격은 주당 $9.83으로, 수여일의 종가와 동일합니다.
이 주식 옵션은 10년의 기간을 가지며 4년에 걸쳐 귀속되며, 첫 해에 25%가 귀속되고, 나머지는 다음 3년에 걸쳐 매달 귀속됩니다. 이 상은 enGene의 2023년 유인 주식 프로그램 외부에서 수여되었으나, 일관된 조건과 조항을 가집니다. 이 상은 NASDAQ 상장 규칙 5635(c)(4)에 따라 독립 보상 위원회에 의해 승인되었습니다.
enGene Holdings Inc. (Nasdaq: ENGN) a accordé une récompense en actions incitative à Joan Connolly, le nouvel directeur technique de l'entreprise. La récompense, accordée le 21 octobre 2024, se compose d'
L'option d'achat d'actions a une durée de 10 ans et sera acquise sur quatre ans, avec 25 % acquis après un an et le reste acquis mensuellement au cours des trois années suivantes. Cette attribution a été faite en dehors du Plan d'Incentive en Actions 2023 d'enGene, mais aura des termes et conditions cohérents. La récompense a été approuvée par le Comité de Compensation indépendant conformément à la Règle d'Inscription NASDAQ 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) hat Joan Connolly, die neue Chief Technology Officer des Unternehmens, einen Anreizlautauftrag gewährt. Der Auftrag wurde am 21. Oktober 2024 gewährt und besteht aus einer nicht qualifizierten Aktienoption zum Kauf von 210.000 Stammaktien zu einem Ausübungspreis von 9,83 USD pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht.
Die Aktienoption hat eine Laufzeit von 10 Jahren und wird über vier Jahre fällig, wobei 25% nach einem Jahr fällig werden und der Rest in den folgenden drei Jahren monatlich fällig wird. Diese Gewährung wurde außerhalb des Anreizaktienplans 2023 von enGene vorgenommen, wird jedoch konsistente Bedingungen und Konditionen aufweisen. Die Auszeichnung wurde vom unabhängigen Vergütungsausschuss gemäß der NASDAQ-Listing-Regel 5635(c)(4) genehmigt.
- Appointment of new Chief Technology Officer, Joan Connolly
- Granted stock option aligns new executive's interests with shareholders
- None.
The inducement award consists of a non-qualified stock option to purchase an aggregate 210,000 of the Company's common shares. The option has an exercise price of
The stock option was granted by the Company's independent Compensation Committee of the Board of Directors as an inducement material to Ms. Connolly entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). While the stock option was granted outside of the Company’s Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, the option will have terms and conditions consistent with those set forth under the Plan.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241022317541/en/
For media: media@engene.com
For investor: investors@engene.com
Source: enGene Holdings Inc.
FAQ
What inducement grant did enGene (ENGN) report under NASDAQ Listing Rule 5635(c)(4)?
When was the inducement grant awarded by enGene (ENGN) to its new CTO?
What is the vesting schedule for the stock option granted by enGene (ENGN)?
How does the exercise price of the stock option compare to enGene's (ENGN) stock price?
